loxl3b Antibody

What is LOXL3 and what are its primary functions in biological systems?

LOXL3 functions as a protein-lysine 6-oxidase that catalyzes the oxidative deamination of peptidyl lysine residues in proteins, converting them to allysine residues. This enzymatic activity is essential for cross-linking in extracellular matrix proteins, particularly in collagens and elastin, providing structural integrity to tissues . LOXL3 demonstrates variable substrate specificity among its isoforms, with isoform 1 showing highest activity toward collagen type VIII, while isoform 2 preferentially acts on collagen type IV .

Beyond matrix remodeling, LOXL3 serves as a regulator of inflammatory responses by inhibiting the differentiation of naive CD4+ T-cells into T-helper Th17 or regulatory T-cells (Treg). This occurs through LOXL3's interaction with STAT3 in the nucleus, where it catalyzes both deacetylation and oxidation of lysine residues on STAT3, disrupting STAT3 dimerization and inhibiting its transcriptional activity . Additionally, LOXL3 plays crucial roles in somite boundary formation by catalyzing fibronectin oxidation, which enhances integrin signaling and myofiber adhesion to the myotendinous junction .

What antibody formats are available for LOXL3 detection and what epitopes do they target?

Current commercial LOXL3 antibodies are available in two primary formats: polyclonal and monoclonal. Polyclonal antibodies, such as Abcam's ab232884, are raised in rabbits against recombinant fragments of mouse LOXL3 (specifically within amino acids 500-750) . These polyclonal preparations typically recognize multiple epitopes across the LOXL3 protein, enhancing detection sensitivity but potentially introducing cross-reactivity.

Monoclonal antibodies, including Abcam's EPR28299-24 (ab319041) and Santa Cruz Biotechnology's A-2, offer enhanced specificity for human LOXL3 . The rabbit recombinant monoclonal antibody format provides consistent lot-to-lot reproducibility with defined epitope targeting. Mouse monoclonal antibodies like A-2 are designed for detection across multiple species including mouse, rat, and human samples .

The epitope selection is critical for experimental design, as antibodies targeting different domains of LOXL3 may yield varying results depending on whether specific isoforms or post-translationally modified forms need detection.

What are the validated applications for LOXL3 antibodies in laboratory research?

LOXL3 antibodies have been validated for multiple experimental applications, with varying degrees of optimization across different commercial sources:

Western blotting represents the most consistently validated application across different antibody sources. In WB applications, researchers have successfully detected LOXL3 protein expression in various tissue lysates and cell cultures, particularly following stimulation with inflammatory cytokines like IL-1β or TGF-β . Immunohistochemistry protocols have been optimized for paraffin-embedded tissues, providing spatial expression data in histological sections .

How should researchers select between different LOXL3 antibodies for specific experimental objectives?

Selection of the appropriate LOXL3 antibody should be guided by several experimental considerations:

• Species compatibility: Determine if the antibody has been validated in your species of interest. For example, ab232884 is validated for mouse samples, while EPR28299-24 is optimized for human applications .

• Application requirements: Consider which detection method will be employed. For complex tissue samples requiring high specificity, monoclonal antibodies may be preferable. For applications requiring enhanced sensitivity, polyclonal preparations might yield better results.

• Isoform recognition: LOXL3 exists in multiple isoforms with differential activity toward extracellular matrix components. Antibodies targeting regions common to all isoforms will detect total LOXL3, while those targeting unique regions may distinguish between specific variants .

• Epitope accessibility: In applications like IHC or IF, epitope accessibility after fixation is crucial. Antibodies recognizing conformation-dependent epitopes may perform poorly in fixed samples compared to those targeting linear epitopes.

• Validation evidence: Review published literature citing specific antibody catalog numbers to evaluate performance in experimental systems similar to your own.

What are the recommended protocols for LOXL3 antibody storage and handling?

To maintain optimal LOXL3 antibody performance, researchers should implement the following storage and handling practices:

• Store antibodies at the recommended temperature (typically -20°C for long-term storage and 4°C for short-term use after reconstitution).

• Avoid repeated freeze-thaw cycles by aliquoting antibodies into single-use volumes upon receipt.

• When diluting antibodies for experimental use, prepare fresh working solutions in appropriate buffers (typically PBS containing 0.1-0.5% BSA or serum from the same species as the secondary antibody).

• Include appropriate protease inhibitors in sample preparation buffers to prevent LOXL3 degradation, particularly when working with tissue homogenates or cell lysates.

• For Western blotting applications, optimize sample preparation methods to ensure adequate protein denaturation without destroying the epitope recognized by the antibody.

How can LOXL3 antibodies be utilized to investigate inflammatory and fibrotic pathways?

LOXL3 antibodies serve as critical tools for investigating inflammatory and fibrotic processes, particularly in conditions like Graves' orbitopathy (GO). Recent research has demonstrated that LOXL3 plays a significant role in mediating both inflammation and fibrosis in orbital tissues .

For investigating inflammatory pathways, researchers can employ LOXL3 antibodies in Western blot analyses following IL-1β stimulation of orbital fibroblasts. Studies have shown that IL-1β (10 ng/mL, 48 hours) substantially increases LOXL3 protein levels along with proinflammatory cytokines like IL-6, IL-8, and ICAM-1 . By combining LOXL3 antibody detection with knockdown experiments (using siRNA targeting LOXL3), researchers can establish causal relationships between LOXL3 expression and downstream inflammatory mediators.

For fibrotic pathway investigation, TGF-β stimulation (5 ng/mL, 48 hours) increases LOXL3 protein production alongside profibrotic proteins such as fibronectin, collagen Iα, and α-SMA . LOXL3 antibodies enable quantification of these expression changes through Western blotting or immunofluorescence. By correlating LOXL3 levels with fibrotic markers, researchers can investigate the molecular mechanisms underlying fibrotic tissue remodeling.

A recommended experimental approach includes:

• Stimulating cell cultures with inflammatory or fibrotic mediators

• Harvesting protein at multiple time points

• Quantifying LOXL3 expression using validated antibodies

• Correlating LOXL3 levels with downstream pathway activation through phosphorylation-specific antibodies targeting NF-κB, Akt, ERK, and JNK

What methodological approaches enable investigation of LOXL3's role in regulating STAT3 signaling?

LOXL3 uniquely regulates STAT3 signaling through its dual enzymatic activities of deacetylation and oxidation of lysine residues. To investigate this regulatory mechanism, researchers can implement several methodological approaches using LOXL3 antibodies:

• Co-immunoprecipitation (Co-IP) assays: Using LOXL3 antibodies for immunoprecipitation followed by Western blotting for STAT3 can reveal direct interactions between these proteins in the nucleus. This approach has demonstrated that LOXL3 interacts with STAT3 and modifies its lysine residues, disrupting STAT3 dimerization and inhibiting its transcriptional activity .

• ChIP-seq analysis: Chromatin immunoprecipitation using LOXL3 antibodies followed by sequencing can identify genomic regions where LOXL3 may colocalize with STAT3, providing insight into how LOXL3 regulates specific gene expression programs.

• Acetylation/oxidation state assessment: After immunoprecipitating STAT3, researchers can probe for acetylated lysines and oxidized lysines (allysine) to determine how LOXL3 modifies STAT3. This is particularly important as oxidation preferentially occurs on acetylated lysine residues .

• Functional readouts of STAT3 activity: Following LOXL3 manipulation (overexpression or knockdown), researchers can employ LOXL3 antibodies to confirm expression changes while simultaneously measuring STAT3-dependent gene expression, providing functional correlation.

A systematic experimental workflow should include:

• Cellular fractionation to isolate nuclear proteins

• Immunoprecipitation with LOXL3 antibodies

• Western blotting for total STAT3, phospho-STAT3, and acetylated STAT3

• Luciferase reporter assays for STAT3 transcriptional activity

• qRT-PCR analysis of STAT3 target genes

How does LOXL3 inhibition affect inflammatory cytokine production and what detection methods are most sensitive?

LOXL3 inhibition through siRNA knockdown significantly attenuates inflammatory cytokine production in various experimental systems. In GO orbital fibroblasts, silencing LOXL3 (using 25 nM siRNA for 48 hours) before IL-1β stimulation substantially reduced the expression of IL-6, IL-8, and ICAM-1 . This regulatory effect appears consistent across both GO and normal orbital fibroblasts.

For detecting these changes in inflammatory cytokine production, researchers can employ multiple complementary techniques:

• Western blotting: Provides semi-quantitative assessment of protein levels when using LOXL3 antibodies alongside antibodies targeting specific cytokines. This technique is particularly useful for monitoring changes in multiple proteins simultaneously .

• ELISA: Offers highly quantitative measurement of secreted cytokines in cell culture supernatants, providing greater sensitivity than Western blotting for detecting small changes in cytokine production.

• Immunofluorescence: Enables visualization of cellular localization patterns and can reveal heterogeneity in cytokine expression across cell populations that might be missed in bulk assays.

• qRT-PCR: Complements protein-level analyses by measuring cytokine transcript levels, particularly useful for establishing whether LOXL3 regulates cytokine expression at the transcriptional level.

For optimal experimental design, researchers should:

• Include appropriate positive controls (e.g., IL-1β stimulation alone)

• Implement time-course experiments to capture the dynamics of cytokine production

• Verify knockdown efficiency using LOXL3 antibodies

• Consider the effects of LOXL3 inhibition on multiple signaling pathways simultaneously, particularly NF-κB and MAPK pathways

What are the optimal conditions for using LOXL3 antibodies in different experimental applications?

Optimization of LOXL3 antibody usage varies significantly across experimental applications:

Western Blotting (WB):

• Recommended dilutions: 1:1000-1:2000 for most commercial antibodies

• Sample preparation: RIPA buffer containing protease inhibitor cocktail for cell/tissue lysis

• Protein loading: 20-30 μg total protein per lane

• Gel percentage: 8-10% SDS-PAGE gels for optimal resolution

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C

• Detection: Enhanced chemiluminescence with exposure optimization

Immunohistochemistry (IHC-P):

• Antigen retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval

• Blocking: 10% normal serum (from same species as secondary antibody) for 1 hour

• Primary antibody dilution: 1:100-1:200

• Incubation: Overnight at 4°C

• Detection: HRP-conjugated secondary antibody with DAB chromogen

• Counterstaining: Hematoxylin for nuclear visualization

Immunofluorescence (IF):

• Fixation: 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilization: 0.1% Triton X-100 for 10 minutes

• Blocking: 1-3% BSA in PBS for 30-60 minutes

• Primary antibody dilution: 1:50-1:200

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Secondary antibody: Fluorophore-conjugated antibodies specific to primary antibody species

• Nuclear counterstain: DAPI or Hoechst 33342

Immunoprecipitation (IP):

• Lysis buffer: Non-denaturing buffer containing 1% NP-40 or 0.5% Triton X-100

• Antibody amount: 2-5 μg per 500 μg of total protein

• Pre-clearing: With protein A/G beads before antibody addition

• Incubation: Overnight at 4°C with gentle rotation

• Washing: Multiple stringent washes with decreasing salt concentration

• Elution: Gentle elution to maintain protein-protein interactions if studying complexes

How can researchers validate the specificity of LOXL3 antibodies in their experimental systems?

Validating LOXL3 antibody specificity is essential for generating reliable research data. Researchers should implement the following validation strategies:

• Positive and negative control samples: Include tissues or cell lines known to express high levels of LOXL3 (positive controls) and those with minimal or no expression (negative controls). For LOXL3, orbital fibroblast cultures stimulated with IL-1β or TGF-β serve as effective positive controls .

• Knockdown verification: Implement siRNA-mediated knockdown of LOXL3 (e.g., 25 nM for 48 hours) and confirm reduced signal intensity in antibody-based detection methods. This approach provides functional validation of antibody specificity .

• Recombinant protein competition: Pre-incubate the antibody with purified recombinant LOXL3 protein before application to samples. Specific antibodies will show diminished signal due to epitope blocking.

• Multiple antibody comparison: Employ different antibodies targeting distinct epitopes of LOXL3. Concordant results across multiple antibodies increase confidence in specificity.

• Mass spectrometry verification: For immunoprecipitation applications, confirm the identity of pulled-down proteins using mass spectrometry rather than relying solely on Western blot detection.

• Isoform-specific detection: When investigating specific LOXL3 isoforms, validate antibody recognition patterns using recombinant isoform proteins as controls. This is particularly important given the differential activity of isoforms toward various collagen types .

• Cross-reactivity assessment: Test antibody reactivity against related LOX family members (LOX, LOXL1, LOXL2, LOXL4) to ensure specificity within this protein family.

What are the key considerations when designing experiments to study LOXL3's role in fibrosis and tissue remodeling?

When investigating LOXL3's contribution to fibrosis and tissue remodeling, researchers should consider several experimental design factors:

• Appropriate model systems: Select cellular or animal models that recapitulate the fibrotic condition of interest. For studying Graves' orbitopathy, orbital fibroblast cultures stimulated with TGF-β (5 ng/mL) provide a relevant model system .

• Temporal dynamics: Implement time-course experiments to capture the progression from acute inflammatory responses to chronic fibrotic changes. LOXL3 expression may vary throughout this process, affecting its functional impact.

• Combinatorial stimulation: In many pathological conditions, multiple stimuli act concurrently. Consider combining inflammatory cytokines (IL-1β) with profibrotic factors (TGF-β) to better model the complex in vivo environment.

• Pathway intersection analysis: LOXL3 influences multiple signaling pathways including Akt, ERK, JNK, and NF-κB . Design experiments to assess how these pathways interact during fibrotic processes, using phospho-specific antibodies alongside LOXL3 detection.

• Matrix protein analysis: Include quantification of LOXL3's substrates, particularly fibronectin, collagen Iα, and α-SMA, which represent key markers of fibrotic transformation .

• Functional assays: Complement protein expression studies with functional assays such as collagen gel contraction, wound healing, or transwell migration to assess the functional impact of LOXL3 on fibroblast behavior.

• 3D culture systems: Consider employing three-dimensional culture systems or organoids that better recapitulate the spatial organization of tissues undergoing fibrotic remodeling.

• Comparative analysis across LOX family members: Design experiments to distinguish LOXL3-specific effects from those mediated by other LOX family proteins, which may have partially overlapping functions.

What techniques enable the study of LOXL3's dual enzymatic activities in cellular contexts?

LOXL3 possesses dual enzymatic activities—protein-lysine 6-oxidase activity and deacetylase activity—that contribute to its diverse biological functions. Studying these activities in cellular contexts requires specialized techniques:

• Dual activity biochemical assays: To assess both oxidase and deacetylase activities, researchers can implement:

  • Amplex Red-based fluorometric assays to detect H₂O₂ production during lysyl oxidase activity

  • Fluorometric deacetylase activity assays using acetylated peptide substrates

• Mass spectrometry-based approaches: For identifying specific modification sites:

  • MALDI-TOF or LC-MS/MS analysis of immunoprecipitated STAT3 to identify both acetylated and oxidized (allysine) residues

  • Quantitative proteomics to compare modification patterns before and after LOXL3 manipulation

• Proximity ligation assays (PLA): To visualize LOXL3's interaction with substrates like STAT3 in intact cells, providing spatial information about where these enzymatic activities occur.

• BRET/FRET-based sensors: Develop biosensors that undergo conformational changes upon deacetylation or oxidation, enabling real-time monitoring of LOXL3 activity in living cells.

• Chemical inhibitor studies: Compare the effects of selective inhibitors targeting either the oxidase activity (e.g., β-aminopropionitrile, β-APN) or potential deacetylase activity to dissect their individual contributions to phenotypic outcomes.

• Engineered LOXL3 variants: Generate point mutations that selectively disrupt either oxidase or deacetylase activity, then compare their functional impacts using LOXL3 antibodies to confirm equal expression levels.

• Activity-based protein profiling: Develop chemical probes that covalently bind to active LOXL3 enzyme, enabling specific detection of the catalytically active portion of the total LOXL3 pool.

How can researchers interpret contradictory results when using different LOXL3 antibodies?

When researchers encounter contradictory results using different LOXL3 antibodies, a systematic troubleshooting approach is essential:

• Epitope mapping: Determine the specific epitopes recognized by each antibody. Contradictory results may arise when antibodies detect different regions of LOXL3, particularly if:

  • One antibody recognizes an epitope subject to post-translational modification

  • Different antibodies preferentially detect specific isoforms

  • Epitope accessibility varies across experimental conditions

• Validation hierarchy: Establish a validation hierarchy among contradictory results by prioritizing:

  • Results obtained with monoclonal antibodies over polyclonal preparations

  • Results corroborated by orthogonal detection methods

  • Results consistent with functional outcomes from knockdown/overexpression studies

• Isoform-specific effects: Consider whether contradictions reflect biological reality of isoform-specific behaviors. The different LOXL3 isoforms exhibit varying substrate preferences, with isoform 1 showing highest activity toward collagen type VIII and isoform 2 preferentially targeting collagen type IV .

• Sample preparation variables: Evaluate whether differences in sample preparation could explain contradictory results:

  • Fixation methods affecting epitope accessibility in IHC/IF

  • Denaturing vs. non-denaturing conditions in WB

  • Extraction efficiency of membrane-associated vs. nuclear LOXL3 pools

• Context-dependent expression: Consider whether contradictions reflect genuine biological variability:

  • Cell type-specific expression patterns

  • Differential regulation under various stimulation conditions

  • Subcellular redistribution under specific experimental conditions

• Antibody validation experiments: Implement side-by-side validation:

  • Parallel knockdown experiments with multiple antibodies

  • Recombinant protein controls with defined concentrations

  • Cross-platform verification using complementary techniques